SCHEMBL6529809

SCHEMBL6529809

CCC(=O)c1ccc(-c2cccc(N)c2C)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
MAPT P10636 5/20 0.40
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
HDAC1 Q13547 1/20 0.38
MAPK1 P28482 1/20 0.37
NPC1 O15118 2/20 0.37
MITF O75030 1/20 0.37
POLB P06746 1/20 0.37
PPARA Q07869 1/20 0.36
TSHR P16473 2/20 0.36
CYP3A4 P08684 1/20 0.36
PIK3CA P42336 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HPGD P15428 3/20 0.35
BTK Q06187 2/20 0.35
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854898 0.77 NPC1 (0.42) ATMMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL13623664 0.76 ATM (0.46) ATMMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL7049515 0.73 MAPT (0.66) ATMMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL30839804 0.73 CYP3A4 (0.48) MAPTALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL3784789 0.73 CYP3A4 (0.48) MAPTALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL29683594 0.73 CYP3A4 (0.48) MAPTALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL8085526 0.72 L3MBTL1 (0.49) MAPTALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL14947562 0.71 MAPT (0.49) ATMMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL14947561 0.71 MAPT (0.49) ATMMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL7701905 0.70 ALDH1A1 (0.53) ATMMAPTALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR ATM 4553/4885MAPT 3392/4885ALDH1A1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.